- Home
- BCAB vs ESLA Comparison
BCAB vs ESLA Comparison
Compare BCAB & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- ESLA
- Stock Information
- Founded
- BCAB 2007
- ESLA 2021
- Country
- BCAB United States
- ESLA United States
- Employees
- BCAB N/A
- ESLA N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAB Health Care
- ESLA Health Care
- Exchange
- BCAB Nasdaq
- ESLA Nasdaq
- Market Cap
- BCAB 27.0M
- ESLA 32.1M
- IPO Year
- BCAB 2020
- ESLA N/A
- Fundamental
- Price
- BCAB $0.32
- ESLA $0.87
- Analyst Decision
- BCAB Buy
- ESLA Strong Buy
- Analyst Count
- BCAB 2
- ESLA 1
- Target Price
- BCAB $1.00
- ESLA $16.00
- AVG Volume (30 Days)
- BCAB 534.1K
- ESLA 59.0K
- Earning Date
- BCAB 05-13-2025
- ESLA 05-14-2025
- Dividend Yield
- BCAB N/A
- ESLA N/A
- EPS Growth
- BCAB N/A
- ESLA N/A
- EPS
- BCAB N/A
- ESLA N/A
- Revenue
- BCAB $11,000,000.00
- ESLA N/A
- Revenue This Year
- BCAB N/A
- ESLA N/A
- Revenue Next Year
- BCAB N/A
- ESLA N/A
- P/E Ratio
- BCAB N/A
- ESLA N/A
- Revenue Growth
- BCAB N/A
- ESLA N/A
- 52 Week Low
- BCAB $0.24
- ESLA $0.63
- 52 Week High
- BCAB $3.53
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- BCAB 47.19
- ESLA 45.09
- Support Level
- BCAB $0.26
- ESLA $0.78
- Resistance Level
- BCAB $0.34
- ESLA $0.95
- Average True Range (ATR)
- BCAB 0.04
- ESLA 0.13
- MACD
- BCAB 0.00
- ESLA 0.00
- Stochastic Oscillator
- BCAB 58.00
- ESLA 46.93
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.